Takashi Shigematsu
Wakayama Medical University
210 Papers
1.6K Citations
Takashi Shigematsu is an academic researcher from Wakayama Medical University. The author has contributed to research in topics: Secondary hyperparathyroidism & Medicine. The author has an hindex of 39, co-authored 202 publications. Previous affiliations of Takashi Shigematsu include Chugai Pharmaceutical Co. & Jikei University School of Medicine.
Chat about Author
Papers
FGF23 modulates the effects of erythropoietin on gene expression in renal epithelial cells
Mitsuru Yashiro,Masaki Ohya,Toru Mima,Ueda Yumi,Yuri Nakashima,Kazuki Kawakami,Ishizawa Yohei,Shuto Yamamoto,Sou Kobayashi,Takurou Yano,Yusuke Tanaka,Kouji Okuda,Tomohiro Sonou,Tomohiro Shoshihara,Yuko Iwashita,Yu Iwashita,Kouichi Tatsuta,Ryo Matoba,Shigeo Negi,Takashi Shigematsu +19 more
TL;DR: The results suggest cross talk between erythropoietin and FGF23 signaling in the regulation of renal epithelial cells in the kidneys other than calcium–phosphorus metabolism.
The Japanese clinical practice guideline for acute kidney injury 2016
Kent Doi,Osamu Nishida,Takashi Shigematsu,Tomohito Sadahiro,N. Itami,Kunitoshi Iseki,Yukio Yuzawa,Hirokazu Okada,Daisuke Koya,Hideyasu Kiyomoto,Yugo Shibagaki,K. Matsuda,Akihiko Kato,Terumasa Hayashi,Tomonari Ogawa,Tatsuo Tsukamoto,Eisei Noiri,Shigeo Negi,Koichi Kamei,Hirotsugu Kitayama,Naoki Kashihara,Toshiki Moriyama,Yoshio Terada +22 more
TL;DR: This clinical guideline for AKI was developed by a multidisciplinary approach with nephrology, intensive care medicine, blood purification, and pediatrics, and clinical practice in Japan was evaluated with comprehensive literature search.
4
Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism.
Takashi Shigematsu,Masafumi Fukagawa,Keitaro Yokoyama,Takashi Akiba,Akifumi Fujii,Atsushi Shinoda,Tadao Akizawa +6 more
TL;DR: This work examined whether dialysate Ca concentrations influence the efficacy and dosing of etelcalcetide with concomitant drugs in secondary hyperparathyroidism.
4
•Journal Article
Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction
TL;DR: The detail and development of phosphate binders is reviewed, recommendation for clinical practice in hyperphosphatemia is recommended and the history of patients with chronic kidney disease is reviewed.
3
•Journal Article
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
Shigeo Negi,Takashi Shigematsu +1 more
TL;DR: There is no evidence of bone toxicity and neurotoxicity of lanthanum carbonate previously reported for aluminium hydroxide, however, further studies are needed to address the longer term toxic effect on bone and other organs.
3